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Abstract
: Type 1 diabetes occurs when self-reactive T lymphocytes destroy the insulin-producing islet E
cells of the pancreas. The defects causing this disease have often been assumed to occur exclusively
in the immune system. We present evidence that genetic variation at the Idd9 diabetes susceptibility
locus determines the resilience of the targets of autoimmunity, the islets, to destruction.
Susceptible islets exhibit hyper-responsiveness to inflammatory cytokines resulting in enhanced cell
death and increased expression of the death receptor Fas. Fas upregulation in E cells is mediated
by TNFR2, and colocalization of TNFR2 with the adaptor TRAF2 in NOD E cells is altered. TNFR2
lies within the candidate Idd9 interval and the diabetes-associated variant contains a mutation
adjacent to the TRAF2 binding site. A component of diabetes susceptibility may therefore be
determined by the target of the autoimmune response, and protective TNFR2 signaling in islets
inhibit early cytokine-induced damage required for the development of destructive autoimmunity.
Reviewers: This article was reviewed by Matthiasvon Herrath, HaraldVon Boehmer, and Ciriaco
Piccirillo (nominated by Ethan Shevach).

Open peer review
Reviewed by Matthiasvon Herrath, HaraldVon Boehmer,
and Ciriaco Piccirillo (nominated by Ethan Shevach). For
the full reviews, please go to the Reviewers' comments section.

Background
The autoimmune nature of type 1 diabetes has led to a
focus on cells of the immune system in the search for
defects that underlie genetic predisposition [1]. Overt diabetes is preceded by an inflammatory islet infiltration,

known as insulitis, that results in the targeted deletion of
insulin-producing E cells and subsequent loss of glucose
homeostasis. However, insulitis does not inextricably lead
to islet destruction, even if significant damage is inflicted.
Cytokines such as TNF, IFNJ and IL1E released by inflammatory cells within islets play an important role in sensitizing E cells to apoptosis and cell death [2]. However, in
non-autoimmune prone individuals, initial islet infiltration and cytokine release may promote repair and regeneration. An aberrant response to inflammatory cytokines
on the part of islets during a critical early stage of autoim-
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munity may therefore contribute to diabetes susceptibility.
Both CD4 and CD8 T cells present in the inflammatory
lesion have the potential to cause E cell loss and both are
required for spontaneous diabetes [3]. MHC Class Irestricted recognition of E cells by CD8 T cells is crucial for
the transition from insulitis to diabetes [4]. Perforin and
Fas-mediated cell death both play a role in CD8-mediated
islet destruction [5]. The targeted release of TNF and IFNJ
upon class I recognition induces islet expression of Fas
[6,7], as well as MHC class I, immunoproteosome subunits [8], and also cytokines such as IL15 [9] and chemokines such as CXCL10/CXCL9 [10] that promote T cell
survival and recruitment. The release of inflammatory
cytokines within islets can therefore promote islet inflammation and cell death, but islets may perhaps normally be
able to regulate pathogenic changes [11].
There is currently limited understanding of how the progression of insulitis to diabetes can be regulated. It has
been shown previously that non-obese diabetic (NOD)
mice expressing B10 resistance alleles at the Idd9 genetic
susceptibility locus, NOD.B10Idd9 congenic mice (Idd9
congenic mice), are highly protected against diabetes [12].
Idd9 genes appear to control the progression from infiltration to islet destruction, and it was proposed that protective Idd9 genes cause the priming of a non-pathogenic
autoimmune response [12]. Establishing the mechanisms
by which protective physiological variants of diabetes susceptibility genes, such as Idd9, prevent diabetes is important for understanding how genetic variation influences
disease susceptibility, and also to discover the natural
points of control at which disease progression can be
averted.
We have discovered evidence that diabetes protection
mediated by Idd9 genes is localized to the target islet tissue
itself. The islet infiltrate in Idd9 congenic mice contains
fewer CD8 T cells, and islets from Idd9 congenic mice are
resistant to CD8 T cell mediated destruction. Idd9 congenic islets demonstrate altered TNF/IFNJ responsiveness
in vitro, with less cell death and reduced Fas expression
compared to NOD islets following cytokine exposure. We
show that TNFR2, and also the TNFR2 signalling adaptor
proteins, TRAF2 and RIP, are expressed in islets, and that
TNFR2-deficient islets are defective in their ability to
upregulate Fas following TNF/IFNJ exposure. TNFR2 signalling is therefore important in mediating TNFresponses in islets. Furthermore, blocking TNFR2 in Idd9,
but not NOD, islets inhibits cytokine-induced Fas upregulation, and the TNF-induced colocalization of TRAF2
with TNFR2 is prolonged in NOD islet E cells. These
results together suggest that the termination of TNFR2 signalling in NOD islets may be defective, and that this trait
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is corrected by Idd9 resistance genes. This raises the possibility that protective islet TNFR2/TRAF2 signaling may
confer resistance to islet destruction and diabetes. An
important implication of these results is that islet defects
can contribute to Type 1 diabetes susceptibility, and that
promoting protective islet responses to cytokines may be
effective in preventing recurrent autoimmune disease and
improve the success of islet tissue replacement therapies.

Results
The islet infiltrate in Idd9 congenic mice contains a
reduced % CD8 T cells
Idd9 congenic mice develop a high degree of insulitis yet
very few go on to develop diabetes [12]. To test for differences in the cellular composition of Idd9 islet infiltrates
we quantified the major leukocyte populations present in
the infiltrate of age-matched 12–14 week old Idd9 congenic and NOD mice by flow cytometry. We observed a
striking reduction in the % CD8 T cells in the Idd9 congenic infiltrates (p = 0.02), as shown in Table 1 and Figure
1(A–B). The reduction in CD8 T cell infiltration was also
evident in situ, by staining pancreatic sections (Figure 1C).
Expression of the activation/memory marker CD44 was
equivalent in both CD4 and CD8 T cell populations
within the islet infiltrate (Figure 1D) suggesting that the
activation state of T cells recruited to the islets is unaffected in Idd9 congenic mice. No significant difference in
the % CD8 T cells in secondary lymphoid organs or
peripheral blood was observed in Idd9 congenic mice
either at 6 weeks of age (Figure 1E), or in older mice (data
not shown). Therefore, the decreased % CD8 T cells is specific to the islet environment.
Islet-reactive CD8 T cells are able to become activated in
the panLN of Idd9 congenic mice
Having found that CD8 T cell infiltration is reduced in
Idd9 congenic islets we wanted to test whether the activation of islet-specific CD8 T cells in lymph nodes is inhibited in Idd9 congenic mice. We transferred CFSE-labeled
splenocytes from a TCR transgenic strain (8.3NODScid)
[13] expressing islet-specific CD8 T cells into Idd9 congenic and NOD recipients. The CFSE+CD8+ (Figure 2A)
populations recovered from the panLN of Idd9 congenic
and NOD recipients were numerically equivalent (Figure
2B) and underwent similar cell division, primarily in the
panLN where the cognate antigen is present (Figure 2C).
We also examined the expression of activation markers on
adoptively transferred 8.3 T cells. CFSE+CD8+ cells
expressed high levels of both CD44 (Figure 2D) and
CD11a (Figure 2E) specifically in the panLN. However,
there was no difference in the expression of CD44 and
CD11a on transferred 8.3 T cells in Idd9 congenic and
NOD mice. The activation of islet-specific CD8 T cells on
the NOD background is therefore not inhibited in the
Idd9 panLN.

Page 2 of 20
(page number not for citation purposes)

Biology Direct 2007, 2:5

http://www.biology-direct.com/content/2/1/5

Table 1: Characterization of major cell types in the Idd9 islet infiltrate

Mean
Gate

CD45+
CD45+
CD45+
CD45+
CD45+

Sem

Idd9

NOD

Idd9

NOD

%CD45

54.2

51.8

4.4

10.0

%CD11b
%CD11c
%B220
%CD4
%CD8

30.8
9.9
42.7
14.0
1.5

26.3
9.9
36.5
16.9
6.8

3.2
1.2
4.0
1.3
0.6

6.2
2.9
6.5
1.0
1.7

Islets isolated from the pancreas of 12 week old female Idd9 congenic (n = 5) and NOD (n = 5) mice using histopaque density gradient and stained
for analysis by flow cytometry to identify the major infiltrating leukocyte populations. Staining for CD45 was used to gate on the leukocyte
population. Representative of two independent experiments.

Idd9 congenic mice retain diabetes protection in the
presence of NOD-derived immune cells, yet there is no
evidence of immune regulation
To test whether the diabetogenic potential of the anti-islet
immune response is reduced in Idd9 congenic mice we
transferred splenocytes from 13 week old Idd9 congenic
and NOD donors into NODScid recipients, or co-transferred 10 million cells from each strain, and monitored
the incidence of diabetes. The transfer of both Idd9 congenic and NOD cells individually induced diabetes in 100
% of recipients (Figure 3A), demonstrating that Idd9
splenocytes have the capacity to induce disease. However,
the onset of disease was delayed in the recipients of Idd9
cells (p = 0.002). Idd9 splenocytes are therefore fully capable of inducing diabetes, but do so with delayed kinetics
compared to NOD splenocytes. The kinetics of diabetes
onset in co-transferred recipients was intermediate
between that seen in recipients of either type of splenocytes alone, demonstrating that although Idd9 congenic
splenocytes are less pathogenic, there is no evidence that
they are able to regulate diabetes induction. This conclusion is further supported by the fact that the diabetes incidence induced by 10 million NOD splenocytes was less at
13 weeks post-transfer (67 %, n = 6, data not shown) than
the 100 % diabetes induced by co-transfer of 10 million
NOD plus 10 million Idd9 splenocytes.

It had previously been suggested that the reason Idd9 congenic mice are protected against diabetes, despite having
an extensive islet infiltrate, could be due to the priming of
a non-pathogenic anti-islet T cell response that releases
the protective cytokine IL4 [12]. To test whether IL4 is
required for the protection mediated by Idd9 genes we
bred Idd9 congenic mice deficient in IL4 (Idd9.IL4KO
mice). As shown in Figure 3B, a high incidence of diabetes
was seen in both NOD (74 % diabetes, n = 23) and
NOD.IL4KO mice (74 %, n = 27), as previously described
[14]. However, Idd9.IL4KO mice developed the same low

frequency of diabetes (3 %, n = 29) as Idd9 congenic mice
(3 %, n = 33), demonstrating that IL4 expression is not
required for diabetes protection in the Idd9 congenic
strain.
We then wanted to test whether Idd9 protection maps to
radiation-sensitive cells of the immune system, or to nonimmune cells. We lethally irradiated (950 Rad) young
Idd9 congenic and NOD mice and reconstituted them
with bone marrow from 6 week old NOD mice. Approximately 70 % chimerism was achieved using this protocol
[see Additional file 1], therefore while some host hematopoetic cells remain the majority are donor derived. The
degree of chimerism was equivalent in the two recipient
strains, therefore previous reports describing the competitive advantage of NOD hematopoetic stem cells in allogeneic recipients are not relevant in this case [15]. Whereas
83 % (n = 12) of NOD mice developed diabetes by 20
weeks following bone marrow transfer, only 8 % (n = 12)
of Idd9 congenic mice developed diabetes (p = 0.0004,
Figure 3C). Idd9 congenic mice therefore retain their protection against diabetes in the presence of NOD-derived
immune cells. Since no evidence of immune regulation
was observed in Figure 3A, this suggests that Idd9 resistance may map to non-lymphoid cells.
To determine whether the chimeric mice exhibit the same
characteristics of disease protection as Idd9 congenic mice,
we used NOD mice expressing the Thy1.1 allele
(NOD.NONThy1.1 mice) as bone marrow donors and
tracked the infiltration of donor CD8 T cells in islets. Six
weeks following irradiation and bone marrow reconstitution, we isolated islet-infiltrating cells from recipients.
While there was no difference in the % Thy1.1+CD4+ cells
in the islets of Idd9 congenic and NOD recipients, the
%Thy1.1+CD8+ cells was significantly reduced (p = 0.01)
in the islets of Idd9 congenic compared to NOD mice (Figure 3D). Both the reduced % CD8 T cells in the islets of
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Figure 1% CD8 T cells in the Idd9 congenic islet infiltrate
Reduced
Reduced % CD8 T cells in the Idd9 congenic islet infiltrate. Islet infiltrating cells were isolated from the islets of Idd9
congenic and NOD mice for analysis by flow cytometry. Dot plots showing representative CD4 and CD8 staining, gated on the
CD45+ population (A), and the range of values for %CD8+ and %CD4+ cells (B) are also shown. Results representative of > 6
independent experiments (mice aged 12–14 weeks). The presence of CD8+ cells in the islets of Idd9 congenic and NOD mice
was also determined by confocal microscopy of frozen pancreatic sections (C). Sections (10 Pm) from 12–14 week old mice
were stained with antibodies to CD8 (green) and insulin (red), and Topro-3 (blue) was used to visualize nuclei. A total of 27
infiltrated islets from 4 Idd9 congenic mice, and 36 infiltrated islets from 4 NOD mice were examined. The islets were imaged
from three different levels through each pancreas, each level separated by at least 300 Pm. Lower panels show fluoroscein
staining only to aid comparison of CD8 infiltration between Idd9 congenic and NOD islets. Islets from the two strains exhibiting similar areas of infiltration were compared (i-iv show minor infiltration, and v-viii an extensive infiltrate). Original magnification 40 ×. In (D), flow cytometry staining of the activation marker CD44 on CD4 and CD8 T cells isolated from the islet
infiltrate of 12–14 week old mice is shown. Bars and adjacent numbers in plot indicate average value. n = 6, representative of 2
independent experiments. The % CD4 and CD8 T cells in peripheral blood and secondary lymphoid organs of 6 week old Idd9
congenic mice was also determined by flow cytometry (E). Average values +/- SEM are shown. n = 4, representative of 2 independent experiments.
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Figure 2 expansion and activation of islet specific CD8 T cells in the panLN of Idd9 congenic and NOD mice
Equivalent
Equivalent expansion and activation of islet specific CD8 T cells in the panLN of Idd9 congenic and NOD mice.
CFSE-labeled splenocytes (20 million cells) from 4–6 week old 8.3NODScid donor mice were transferred into age-matched 6–
9 week old Idd9 congenic and NOD recipients. On day 4 following transfer panLN and ingLN cells were stained for analysis by
flow cytometry. Donor islet-specific CD8 T cells were defined by gating on CFSE+CD8+ cells (A). The percentage of
CFSE+CD8+ T cells recovered from the panLN of Idd9 congenic and NOD mice is shown in (B). Representative CFSE profiles
of CFSE+CD8+ cells in the panLN and ingLN, with the average % divided cells +/- SEM, are shown in (C). We also stained for
the activation markers CD44 (D) and CD11a (E), and representative histograms (gated on CFSE+CD8+ cells) are shown for
Idd9 congenic and NOD panLN and ingLN cells, indicating the average value +/- SEM. Data is representative of 4 independent
experiments n = 5–6 mice for each experiment.
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ulation
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Figure
3
mice retain diabetes protection in the presence of NOD-derived bone marrow, yet no evidence of immune regIdd9 congenic mice retain diabetes protection in the presence of NOD-derived bone marrow, yet no evidence
of immune regulation. (A) Diabetes incidence in NODScid recipients following adoptive transfer of 20 million splenocytes
from 13 week old NOD (n = 6) and Idd9 congenic (n = 4) mice, or co-transfer of 10 million NOD plus 10 million Idd9 congenic
splenocytes (n = 6) determined by weekly blood glucose monitoring. The results are representative of 2 experiments. (B)
Blood glucose levels measured weekly from 15 weeks of age in female NOD (n = 23), NOD.IL4KO (n = 27), Idd9 congenic (n
= 33), and Idd9.IL4KO (n = 29) mice until 33 weeks of age to determine diabetes incidence. In (C), diabetes incidence is shown
for lethally irradiated (950 Rad) Idd9 congenic and NOD mice reconstituted with bone marrow cells (10 million) from 5 week
old NOD donors. Results representative of 2 independent experiments. In (D) bone marrow cells (10 million) from
NOD.NONThy1.1 donors were injected as in (C). Islet-infiltrating cells were isolated from recipients 6 weeks following transfer and the % donor (Thy1.1+) CD4 and CD8 T cells determined by flow cytometry.
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Idd9 congenic mice and the protection against diabetes
therefore appear to correlate with expression of Idd9 gene
products in radiation-resistant cells.
Transplanted Idd9 congenic islets are resistant to
destruction by islet-specific CD8 T cells
The results of the bone marrow reconstitution experiments suggested the possibility that at least a component
of the protective effect of Idd9 genes may be mediated by
non-immune cells. To determine whether protection is
localized to the islet tissue we tested whether islets from
Idd9 congenic mice are resistant to autoimmune destruction. Since we observed a reduced % CD8 T cells in Idd9
congenic islets, we hypothesized that islet resistance to
CD8-mediated autoimmunity may be specifically
affected. We transplanted islets isolated from 5 week old
Idd9 congenic and NOD mice under the kidney capsule of
immunodeficient NODScid recipients. Islets from young
mice with minimal insulitis damage were used as donors
and the islets were cultured for several days before transplant to deplete tissue-resident leukocytes. The transplanted mice were injected with splenocytes from
8.3NODScid TCR transgenic mice and then five days later
grafts were taken and the extent of destruction determined
by histology (Figure 4A). We observed that Idd9 islet tissue remained intact while the 8.3 CD8 T cells destroyed
NOD islets. To quantitate the extent of graft destruction
we scored the number of healthy islets in each graft using
glucagon staining to reveal the presence of islet remnants.
Healthy islets show the typical distribution of glucagonpositive cells scattered around the islet periphery, whereas
islets in which the core of target insulin-producing cells
has been destroyed exhibit a collapsed glucagon-positive
remnant. Control grafts, in recipients where no CD8 T
cells were transferred, from both Idd9 congenic and NOD
donors were healthy. In grafts from mice that were
injected with islet-specific CD8 T cells, on average only 42
% of NOD islets, compared to 88 % Idd9 congenic islets
(p = 0.004), were scored as healthy (Figure 4B). Islets from
Idd9 congenic mice therefore possess an intrinsic capacity
to resist CD8-mediated autoimmune destruction.
Idd9 congenic islets exhibit reduced sensitivity to the
inflammatory cytokines TNF and IFNJ
NOD islets can be induced to undergo cell death in vitro
by treatment with TNF in combination with IFNJ [16]. In
order to determine whether cytokine-responsiveness is
altered in Idd9 congenic islets we tested whether sensitivity to in vitro cytokine-induced cell death is reduced. Since
islet cells can undergo cell death when dispersed into single cells we chose to stain live intact islets with a fluorescent live/dead viability stain and electronically quantitate
the % dead cells from confocal images. As shown in Figure
4C–D, cytokine treatment induced a significantly greater
amount of cell death in NOD islets compared to Idd9

http://www.biology-direct.com/content/2/1/5

islets (p = 0.01). Islets from Idd9 congenic mice therefore
display altered cytokine-responsiveness compared to
NOD and are resistant to the cytotoxic effects of TNF/IFNJ
treatment in vitro.
TNFR2 mediates E cell upregulation of the death receptor
Fas in response to cytokines
The TNFR2 gene lies within the Idd9 congenic interval and
the NOD allele generates a protein with 5 amino acid variants compared to the diabetes resistant B6 strain [17].
TNFR2 is therefore a potential candidate gene for the
altered responsiveness to TNF/IFNJ we observe in Idd9
islets. TNFR2 mRNA expression has been shown to be
induced in islet cells during diabetes progression [18]. To
test whether TNFR2 protein is expressed in islet E cells of
diabetes susceptible and resistant strains, we analysed dispersed islets from 5 week old NOD and Idd9 congenic
mice by flow cytometry. Using the characteristic autofluoresence in the FL1 channel as a E cell marker [19], we
found that approximately 3 % E cells are TNFR2 positive
(Figure 5A). Immunohistochemical staining of pancreatic
sections from 12 week old Idd9 congenic and NOD mice
confirmed that a sub-population of islet E cells in both
strains express TNFR2 protein, whereas no staining
occurred using the secondary antibody alone, or in islets
from B6.TNFR2KO mice (Figure 5B).

One of the key changes that occurs in E cells in response
to cytokines is the upregulation of the death receptor Fas
[20], and Fas upregulation may play a role in the process
of autoimmune islet cell death in vivo. We therefore tested
whether TNFR2 expression in islets is required for Fas
upregulation following cytokine treatment. Intact islets
from B6 mice were treated for 48 hours with medium,
TNF, IFNJ, or with a mixture of TNF and IFNJ, then dispersed and stained with antibodies to Fas or isotype control for analysis by flow cytometry. Fas induction occurred
only in the presence of IFNJ and TNF, not with either
cytokine alone (Figure 6A). To test the role of TNFR2 in
Fas induction, we then treated islets from B6 and
B6.TNFR2KO with TNF/IFNJ, or with medium alone. As
shown in Figure 6B–C, Fas upregulation following IFNJ/
TNF treatment was signficantly reduced in B6.TNFR2KO
islets compared to B6 islets (p = 0.0003). Fas upregulation
was not completely abolished in B6.TNFR2KO islets following TNF/IFNJ-treatment, therefore it is likely that
TNFR1 also contributes to Fas upregulation. However,
TNFR2 clearly mediates Fas upregulation in E cells in
response to cytokines.
Blocking TNFR2 inhibits Fas upregulation in Idd9, but not
NOD islets
We therefore tested whether Fas induction is also reduced
in Idd9 congenic islets. Intact islets from 5 week old
donors were again used to minimize insulitis damage and
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Figure
Islets from
4 Idd9 congenic mice are intrinsically resistant to cytokine and CD8 T cell-mediated autoimmune destruction
Islets from Idd9 congenic mice are intrinsically resistant to cytokine and CD8 T cell-mediated autoimmune
destruction. Islets isolated from 5 week old Idd9 congenic and NOD donors were transplanted under the kidney capsule of
NODScid recipients. After allowing 7 days for the grafts to revascularize, splenocytes from 8.3NODScid mice (30 million cells)
were adoptively transferred into graft recipients. Control mice did not receive splenocytes. Five days later, graft destruction
was analyzed by H&E staining of graft sections, as shown in (A) (i-iv). Scoring of graft destruction (B) was determined by antiglucagon staining (A) (v-vi) as described in the methods. NOD grafts (n = 4), NOD control grafts (n = 2), Idd9 congenic grafts
(n = 3) and Idd9 control grafts (n = 2) were assessed, and a total of 24, 11, 26 and 32 islets scored, respectively, for each group.
Graph shows average % healthy islets in each graft +/- SEM. Results representative of 3 independent experiments. (C) Confocal
live/dead viability staining of islets from 5 week old Idd9 congenic and NOD mice treated with, or without, TNF (2,000 U/ml)
and IFNJ (1,000 U/ml) for 6 days. Live cells stain green, and the nuclei of dead cells stain red. For each assay, 7–9 islets (250–
500 cells) were analyzed and the average % dead cells per field +/- SEM is shown in (D). Results representative of 3 independent experiments.
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Figure 5 of TNFR2 expression in islet cells
Detection
Detection of TNFR2 expression in islet cells. (A) Flow cytometry staining with anti-TNFR2 antibody and isotype control
in islets isolated from 5 week old mice and cultured for 4–5 days. Auto-fluorescence in the FL1 channel was used to gate on
the E cell population, and dead cells were excluded using 7AAD. The gated cells were negative for the hematopoetic cell
marker CD45. Values given are the average %TNFR2+ cells +/- SEM (n = 4 each strain), gated on FL1+ cells and corrected for
background isotype control staining. Results representative of 3 independent experiments. (B) Immunohistochemical staining
of paraffin sections from TNFR2KO (i, iv), 12–14 week old NOD (ii, v) and Idd9 congenic (iii, vi) pancreas stained with antibodies to TNFR2 (i-iii) or with the secondary antibody alone (iv-vi). Pancreatic sections from 3 different Idd9 congenic and NOD
mice, and 1 B6.TNFR2KO mouse, were examined.
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Figure mediates
TNFR2
6
Fas upregulation, and blocking TNFR2 inhibits Fas upregulation in Idd9 congenic but not NOD islets
TNFR2 mediates Fas upregulation, and blocking TNFR2 inhibits Fas upregulation in Idd9 congenic but not
NOD islets. (A) Islet Fas expression is induced only by combined TNF+IFNJ treatment. Intact islets from B6 mice were
treated with medium, 1,000 U/ml IFNJ and 1,000 U/ml TNF, alone and in combination, for 48 hours. Islets were then dispersed
into single cells and, after 60 min recovery incubation, stained with antibodies to Fas or the relevant isotype control for anlysis
by flow cytometry. The average %Fas+ cells for each treatment, gated on live FL1+ E cells, is shown. (B) TNFR2 mediates Fas
upregulation in E cells. Islets from B6 and B6.TNFR2KO mice (pooled from 2 mice for each strain) were treated in triplicate
with medium or IFNJ +TNF (both at 1,000 U/ml) for 48 hours and stained with antibodies to Fas as in (A). Control samples
were stained with the relevant isotype control. The % Fas+ cells +/- SEM, gated on live FL1+ E cells, is shown in (C). Representative of 4 independent experiments. (D) Blocking TNFR2 inhibits the upregulation of Fas in E cells from Idd9 congenic but
not NOD mice. Islets from 5 week old Idd9 congenic and NOD mice were treated as before, except that IFNJ +TNF treated
islets were pre-incubated for 60 min with 2 Pg/ml blocking anti-TNFR2 antibody (I+T+R2), or the relevant isotype control
(I+T). Representative dot plots are shown and values indicate the average %Fas+ cells (isotype corrected), gated on live FL1+ E
cells, and this data +/- SEM is plotted in (E). The data was pooled from 6 separate experiments with total n = 13–14.

Page 10 of 20
(page number not for citation purposes)

Biology Direct 2007, 2:5

were treated with IFNJ, or a mixture of IFNJ and TNF. As
shown in Figure 6D–E, Fas expression was significantly
greater in NOD compared to Idd9 islets (p = 0.03) following treatment with IFNJ/TNF, further supporting the idea
that NOD islets exhibit an enhanced responsiveness to
cytokines and that this trait is corrected by expression of
protective Idd9 gene variants. To test whether TNFR2 signals are involved in mediating this this enhanced responsiveness in NOD islets, we also pretreated islets with a
blocking anti-TNFR2 antibody, or with an isotype control,
to test whether this would ablate the increased cytokine
responsiveness in NOD islets. While Fas upregulation was
significantly inhibited in Idd9 islets by addition of the
blocking TNFR2 antibody (36 % decrease, p = 0.02), Fas
induction was only slightly decreased in NOD islets by the
presence of the blocking antibody (13 % decrease). This
suggests that TNFR2-mediated Fas upregulation in NOD
islets is refractive to inhibition compared to Idd9 islets.
Colocalization of TRAF2 with TNFR2 is impaired in NOD
islet E cells
TNFR2 signaling in other cell types is known to be mediated via adaptor proteins, particularly RIP and TRAF2, that
link the cytoplasmic domain of the receptor to downstream intracellular signaling molecules [21]. We therefore determined whether these adaptors are expressed in
islets from Idd9 congenic and NOD mice, and tested
whether cytokine treatment differentially affects their
expression. Immunohistochemical staining of pancreatic
sections from 12 week old mice with antibodies to TRAF2
revealed a distinctive staining pattern concentrated in a
peri-nuclear compartment (Figure 7A). We then showed
by immunoblotting that both TRAF2 (Figure 7B) and RIP
(Figure 7C) are expressed in isolated islets. Treatment of
intact islets with TNF/IFNJ for 2 days increased the
amount of RIP present by approximately 2-fold, while
TRAF2 expression was not altered. However, significant
differences in the expression of adaptor molecules
between Idd9 congenic and NOD islet lysates were not
observed. Therefore, while differential signaling downstream of TNFR2 may occur in NOD and Idd9 congenic
islets, it is not likely to be primarily exerted at the absolute
level of RIP or TRAF2 protein.

The NOD variant of TNFR2 contains a mutation (C436Y)
[17] adjacent to the TRAF2 consensus binding motif (426SXEE-429) [22] and flanking sequences are thought to
modulate TRAF2 binding [23]. We therefore tested
whether altered recruitment of TRAF2 by TNFR2 variants
could potentially explain the differential responsiveness
to TNF/IFNJ that we observed in the islets of Idd9 congenic mice. We examined the kinetics of colocalization of
TNFR2 and TRAF2 in dispersed islet cells following
cytokine stimulation in vitro. Dispersed islet cells isolated
from young donors were treated with TNF and IFNJ for 0,
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30 and 60 minutes and stained sequentially with antibodies to TNFR2, TRAF2 and insulin for analysis by confocal
microscopy. DAPI was used as a nuclear dye, and an ethidium bromide derivative used to exclude dead cells from
the analysis. Additional cells were stained in parallel
minus either the TNFR2 or TRAF2 primary antibody and
non-specific staining was not observed. These controls
were also used to set the staining threshold for analysis.
The colocalization coefficient (M1) of TNFR2 with TRAF2
was then determined for insulin positive TNFR2 expressing E cells at each timepoint. The majority of cells were
insulin positive and very few dead cells were observed.
TNFR2 positive cells were defined as more than 10 pixels
above threshold per cell.
At the zero and 30 minute timepoints the colocalization
coefficient in both Idd9 congenic and NOD cells was
equivalent (approximately 0.6), as shown in Figure 7D–E.
At these timepoints, TRAF2 was seen to be primarily concentrated in a peri-nuclear compartment in both strains.
TRAF2 remained confined to the peri-nuclear compartment in NOD islet cells at 60 minutes. However, after 60
minutes of cytokine treatment few Idd9 cells exhibited this
staining pattern and a weak diffuse cytoplasmic staining
was more commonly observed instead. Our quantitative
analysis indicated that at the 60 minute timepoint the
colocalization coefficient was significantly greater in
NOD cells compared to Idd9 cells (p = 0.02). Colocalization appeared strongest in this peri-nuclear compartment,
and therefore the redistribution of TRAF2 in Idd9 cells at
60 minutes after cytokine treatment is likely to account for
the decreased M1 value. TNFR2 activation is associated
with TRAF2 translocation to the ER [24]. The data therefore suggests that TNFR2 signaling is aberrantly sustained
in NOD islet E cells following TNF exposure.

Discussion
The results of this study suggest that resistance to autoimmune destruction can be controlled by the target islet
cells, and the trait is genetically variable and determined
by genes within the Idd9 interval. While Type 1 diabetes
has traditionally been viewed as a disease of the immune
system there is increasing support for the idea that islet
responses are required for the progression to a destructive
autoimmunity [25], and that defects in the target islet tissue may play a role in disease susceptibility. For example,
in NOD mice blocking interferon signaling in E cells is
protective against diabetes, particularly CD8-mediated
diabetes, demonstrating the importance of islet cytokineresponsiveness for the induction of E cell death [6,26].
The ALR (alloxan-resistant) strain has a dominantly inherited systemic ability to dissipate free-radical stress. Islets
from ALR mice are also resistant to diabetogenesis and
CD8-mediated cytolysis, and appear able to retain insulin-secretory function following cytokine- or glucose-
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Co-localization
Figure 7
of TRAF2 and TNFR2 following cytokine treatment is prolonged in NOD E cells
Co-localization of TRAF2 and TNFR2 following cytokine treatment is prolonged in NOD E cells. Expression of
the adaptor molecules TRAF2 and RIP in islets. (A) Immunohistochemical staining of pancreas sections from 12–14 week old
NOD and Idd9 congenic mice with anti-TRAF2 antibody. Immunoblotting with antibodies to TRAF2 (B) and RIP (C) of protein
lysates prepared from 5 week old Idd9 congenic (I) and NOD (N) islets stimulated for 3 days +/- 1,000 U/ml TNF + 1,000 U/ml
IFNJ. In each case, membranes were stripped and re-blotted with antibodies to actin as loading control. Results representative
of 2–3 independent experiments. (D) Co-localization of TRAF2 and TNFR2 following cytokine treatment determined by confocal imaging. Representative images of E cells from 5 week old NOD and Idd9 congenic mice treated with 1,000 U/ml IFNg +
1,000 U/ml TNF for 0, 30 and 60 minutes, stained with antibodies to TNFR2, TRAF2 and insulin, and the nuclear dye DAPI.
The merged image of TNFR2 (green), TRAF2 (red) and DAPI (blue) is also shown. Dead cells were excluded using an EtBrderived dye. In (E) the average TNFR2/TRAF2 colocalization coefficient (M1) +/- SEM is shown for each time point. TNFR2
positive cells are rare within the islet population, but on average 18 TNFR2 positive cells were analyzed per treatment. The
threshold for TNFR2 and TRAF2 staining was determined by staining an aliquot of the cells in parallel minus each primary antibody.
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induced stress in vitro [27]. Transgenic expression of a
B2M allele associated with diabetes protection has also
been suggested to exert protection through non-hematopoetic cells [28]. Thus, islet mediated protection from
autoimmunity has been demonstrated in several experimental models.
We found that splenocytes from Idd9 congenic mice possess the potential to transfer disease, demonstrating that
the immune system in Idd9 congenic mice is fully capable
of mounting a pathogenic anti-islet autoimmune
response. Adoptive transfer to immunodeficient mice can
reveal latent pathogenicity that may be less evident in
immunosufficient hosts, and the onset of disease induction was delayed compared to NOD mice. Therefore, the
possibility remains that an additional component of Idd9
genetic susceptibility affects the development of autoreactivity. At least three genes mediate diabetes protection in
the Idd9 congenic strain used in this study [12], suggesting
that other factors are likely to also be involved. Studies by
other groups have found that CD8 T cell tolerance [29]
and also T cell responsiveness to 4-1BB ligand [30] are
affected by genes in the Idd9 interval. However, we have
shown that Idd9 congenic mice depleted of immune cells
retain their protection against disease in the presence of
NOD-derived immune cells, and that transplanted islets
from Idd9 congenic mice resist CD8-mediated destruction. The data therefore suggests that a component of diabetes resistance mediated by protective Idd9 genes maps
to the target islets. It is conceivable that islet responses
during the early stages of inflammation may influence the
control of CD8 T cell tolerance described by Martinez et al
[29]. Furthermore, the target-organ specificity of protection mediated by Idd9 genes is supported by a recent publication demonstrating that diabetes-protective B10
alleles at the Idd9 locus do not protect against autoimmunity in a non-islet target, in experimental autoimmune
encephalitis [31].
It is interesting to consider how islet resistance to destruction by autoimmune CD8 T cells is related to our initial
observations that the infiltrate in Idd9 congenic islets contains a reduced number of CD8 T cells. One potential
explanation for the reduction in CD8 T cells is that their
survival or retention in islets is dependent on cytokineinduced modifications that do not occur in the islets of
Idd9 congenic mice. The actions of TNF and IFNJ induce a
diverse program of changes in islets that can greatly
increase their visibility to the immune system and support
the accumulation of inflammatory cells, for example by
the release of chemokines and cytokines. Protective
cytokine responses in Idd9 islets may inhibit a range of
pro-inflammatory changes that occur in NOD islets to
promote the transition from islet infiltration to a destructive autoimmunity.
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Both islet cell death and Fas expression are enhanced in
NOD compared to Idd9 islets following exposure to the
inflammatory cytokines TNF and IFNJ in vitro, suggesting
that NOD E cells are hyper-responsive to these cytokines.
NOD mice are known to express an allelic variant of one
of the receptors for TNF, TNFR2, that is distinct from that
expressed by the diabetes resistant C57BL6 strain [17].
TNFR2 maps within the Idd9 congenic interval and is
therefore a plausible candidate gene for the Idd9-mediated
control of TNF/IFNJ responsiveness and islet resistance
[12]. We found that TNFR2 mediates the induction of Fas
expression by islet E cells following cytokine exposure.
Furthermore, TNFR2 inhibition was ineffective at reducing Fas expression in NOD E cells, whereas Idd9 islets were
responsive to the antibody treatment. This suggests that
TNFR2 signal termination may be impaired in NOD mice.
TNFR2 signaling depends on recruitment of the TRAF2
adaptor protein. TNFR2 activation is followed by translocation of TRAF2 to the ER, where it is ubiqutinated and
degraded resulting in signal termination [24,32]. We
observed this process in Idd9 islets, which showed only
low levels of colocalized TNFR2 and TRAF2 after 60 minutes of cytokine exposure. However, in NOD islet cells
TRAF2 was found to remain associated with TNFR2. NOD
E cells therefore appear to exhibit impaired termination of
TNFR2 signaling that results in exaggerated cytokine
responsiveness as evidenced by increased Fas receptor
expression and cytokine induced death.
The cytoplasmic C436Y mutation in the NOD isoform of
TNFR2 lies adjacent to the binding site for TRAF2 [22].
Structures sufficiently similar to the TNFR2 C436Y region
to precisely model the effect of this mutation on TRAF2
binding are not currently available. However, examination of published structures for a TNFR2 peptide bound to
TRAF2 (1CA9), and a LTE R peptide bound to TRAF3
(1RF3) [33,34] suggests that residue 436 is located at the
surface of the TNFR2 protein, and supports the hypothesis
that introduction of tyrosine at this position may alter the
stability of the binding interface between TRAF2 and
TNFR2. One potential rationale for the aberrantly sustained signaling by the NOD TNFR2 isoform is that
TRAF2 binding is more stabilized and induces stronger
pro-inflammatory responses.
The molecular pathway to islet cell death mediated
through TNFR2 is also a matter of interest. TNFR2 signaling can activate NF-kB through TRAF2. It has been shown
in human islets that cytokine-induction of Fas expression
is associated with NF-kB activation [35]. While TNF signaling through TNFR2 may affect the internal sensitivity of
E cells to cell death, TNFR2 activation of NF-kB may act
primarily to induce cellular changes that promote islet
inflammation and susceptibility to CTL killing. TNFR2mediated Fas induction on E cells, which is heightened in

Page 13 of 20
(page number not for citation purposes)

Biology Direct 2007, 2:5

NOD mice, may promote islet sensitivity to CD8-mediated destruction. While TNFR1-dependent islet responsiveness has been shown to be critical for islet destruction
by CD4 T cells [36], islet TNFR2 responses were not
required for this CD4-mediated diabetes. Islet TNFR2 may
therefore function primarily in licensing CD8 cytotoxicity.
It has been proposed that avidity maturation of the low
affinity self-reactive CD8 response may be dependent on
early islet damage mediated by death receptors such as Fas
[37], and potentially other receptors such as HVEM/
TRAIL-R [38,39] could also be involved. However, Fasdeficient islets transplanted into wild type NOD mice are
only slightly protected against destruction [40], and Fas
deficient islets are also not protected in CD8-mediated
TCR transgenic diabetes models [5,7]. Blocking multiple
TNFR molecules increases diabetes protection, for example, by overexpression in islets of dominant negative
FADD, the adaptor protein used by multiple death receptors to recruit and activate caspase-8 [41]. Furthermore,
islet overexpression of decoy-receptor 3 (DCR3), that
inhibits Fas, LTE R and DR3 signaling, protects against
diabetes and also reduces insulitis [42]. However, the program of cytokine-induced changes that affect islet infiltration and survival is likely to be wide-ranging, and the
control of death receptor expression perhaps only one
aspect of this. Further studies will be required to test the
precise effects of the NOD TNFR2 mutations on TRAF2dependent signaling and in mediating downstream effects
on islet survival.
TNFR2 is also expressed on T cells following activation
and is thought to act as a co-stimulatory molecule [43-46].
We have not addressed the effect of NOD TNFR2 mutations in T cells, but the signaling pathways activated by
members of the TNFRSF appear to be cell and context
dependent and it is possible that TNFR2 plays quite distinct roles in lymphoid and target cells. While TNFR2deficient NOD mice are not protected against diabetes
[47] the effect of TNFR2-deficiency in immune cells may
mask the role of TNFR2-deficiency in islets. Indeed, it has
been shown that systemic TNFR2-deficiency increases
effector CD8 responses [48].
TNFR2 polymorphisms in human populations have been
associated with susceptibility to inflammatory disease, in
particular rheumatoid arthritis, systemic lupus erythematosus and Crohn's disease [21,49]. This supports there
being an important role for TNFR2 in determining TNF
responses and inflammatory disease pathogenesis, and
further genetic and functional experiments will be
required to test the importance of TNFR2 variants in controlling islet responses and diabetes susceptibility.
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Materials and methods
Animals
NOD.B10Idd9R28 mice (line 1104) containing B10
genome across all three Idd9.1/9.2/9.3 intervals (48 cM),
referred to here as Idd9 congenic mice, were obtained
from Taconic Farms (Idd9R28, line 1104) and maintained
in the rodent breeding colony at The Scripps Research
Institute (TSRI). NOD and NODScid mice were obtained
from the rodent breeding colony at TSRI. 8.3NODScid
mice [13] were kindly provided by Dr. Pere Santamaria
(University of Calgary), and a colony is maintained at
TSRI. NOD.IL4KO mice were obtained from Jackson
(stock 004222) and crossed with Idd9 congenic mice.
NOD, NODIL4KO, Idd9 and Idd9IL4KO mice were generated by intercross of appropriate progeny and used as
internal controls. Fluorescent genotyping using the polymorphic markers D4Mit63, D4Mit72, D4Mit28 and
D4Mit180 was used to ensure retention of the entire Idd9
congenic interval during intercross. B6.TNFR2KO mice
were obtained from Jackson (stock 002620). Female mice
were used for all experiments. All live animal experiments
were approved by the Institutional Animal Care and Use
Committee (IACUC) and the Animal Research Committee (ARC) and were conducted in accordance with institutional guidelines for animal care and use.
Diabetes Incidence
Diabetes incidence was determined by monitoring blood
glucose levels weekly using Glucometer Elite strips. Mice
with two successive blood glucose levels greater than 300
mg/dl were considered diabetic.
Isolation of leukocytes from pancreatic islet tissue
Pancreas tissue was taken from 12 week old Idd9 congenic
and NOD mice and, after removal of all panLN, immediately cut into small pieces and digested in 1 mg/ml collagenase P (Roche) in complete DMEM for 20 minutes at
37° with agitation. After washing, the digested pancreas
was layered over Histopaque 1077 (Sigma) and the islets
recovered from the interface after centrifugation. Following further washes, the islets were treated with 0.05 %
trypsin/EDTA (Gibco) to create a single cell suspension.
Leukocytes released from the trypsinized islets were incubated in DMEM at 37° for between 60 and 90 minutes to
allow recycling of cleaved surface molecules. Cells were
then counted by trypan blue exclusion and stained for
analysis by flow cytometry. An antibody to CD45 was
included in the staining in order to compare leukocyte
subpopulations as a percentage of infiltrating cells, independently of the extent of infiltration. All antibodies used
for flow cytometry were obtained from BD Pharmingen.
Staining was performed according to standard procedures.
A FACSCaliber dual laser cytometer was used in conjunction with CellQuest software for data acquisition and
analysis.
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Immunohistochemistry
Freshly isolated pancreas tissue from 12–14 week old Idd9
congenic and NOD mice was snap frozen in OCT medium
(CD8 staining) or fixed in 10 % NBF and paraffin-embedded (TNFR2 and TRAF2 staining). For CD8 staining, sections (10 Pm) were cut from three different levels from
each pancreas, each level separated by 300 Pm, and air
dried at room temperature overnight. Absolute ethanol
was used for fixation, and 10 % normal goat serum, or
BSA, was used as blocking agent. Anti-insulin (Dako,
Carpinteria, 1/400) and anti-CD8 (BD Pharmingen, San
Diego, 1/100) primary antibodies were incubated overnight at 4°. Texas Red conjugated anti-guinea pig (1/100)
and Fluoroscein conjugated anti-rat (1/200) secondary
antibodies (both from Vector) were incubated for 1 hour
at room temperature in the dark. Topro-3 was used to
stain nuclei and was added to anti-fade component A
(Molecular Probes, Eugene OR) when mounting the
slides. Slides were stored at -80° until analyzed using BioRad MRC1024 laser scanning confocal microscope and 40
× oil objective lens, using Bio-Rad LaserSharp (v3.2) software to collect images. For colocalization studies, polyclonal goat anti-TNFR2 (R&D systems, 1/10 dilution),
donkey anti-goat-fluoroscein (Molecular Probes, Eugene
OR, 1/50), rabbit anti-TRAF2 (Leinco, 1/10-1/50 dilution), donkey anti-rabbit-Cy 5 (Jackson, 1/50), anti-insulin and donkey anti-guinea pig-Texas Red (Jackson, 1/50)
were added sequentially for co-localization studies. DAPI
was included in the mounting medium (Vector). Sections
from B6.TNFR2KO mice stained with anti-TNFR2 antibody in parallel did not show specific staining. The TRAF2
antibody used for staining sections gave a single band
when used for western blotting, demonstrating its specificity for the TRAF2 protein. Slides were stored at 4° until
analyzed using a Bio-Rad (Zeiss) Radiance 2100 Rainbow
laser scanning confocal microscope and 60× objective
with 2.5× magnification. Zeiss LSM Examiner software
used to determine M1 colocalization coefficient. Non-fluorescent TNFR2 and TRAF2 staining was performed on
12–14 week old pancreas sections as above except using
DAB (Vector) to develop the signal.
Adoptive transfer of 8.3NODScid splenocytes
Whole splenocytes from 4–6 week old 8.3NODScid mice
were used in all experiments. Where CFSE labeling was
required whole splenocytes were incubated in PBS at 5 ×
10'7 cells/ml with 5 mM CFSE (Molecular Probes, Eugene
OR) for 10 min at 37°. The cells were then washed twice
in cold PBS and 20 million labeled cells were injected iv
into recipient mice. The recipients of CFSE-labeled
8.3NODScid splenocytes were aged between 6 and 9
weeks of age, and were age-matched in each experiment.
For the transplant experiments, Lympholyte M (Cedarlane
Laboratories, Ontario, Canada) was used in some cases,
according to the manufacturer's instructions, to remove
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dead cells and red blood cells, and 30 million unlabeled
8.3NODScid splenocytes were injected iv per mouse. A
sample of the injected cells was labeled with antibodies to
CD8 and VE 8.1/8.2 to confirm that all CD8 T cells
injected were positive for the 8.3 TCR (CD8+ gated cells
were 97–99 % VE 8.1/8.2+). To determine the activation
phenotype the cells were also labeled with antibodies to
CD44. The CD8+VE 8.1/8.2+ cells were typically approximately 40 % CD44hi. For CFSE transfer experiments
panLN and ingLN from recipient mice were taken 4 days
post-injection and single cell suspensions prepared in
sterile filtered Hanks medium containing 5 % FBS. The
cells were then stained with antibodies to CD8, CD44 and
CD11a for analysis by flow cytometry.
Adoptive transfer of diabetes
Donor splenocytes from 13 week old Idd9 congenic and
NOD mice were lysed to remove red cells and injected iv
into NODScid recipient mice. Either 20 million Idd9 congenic or NOD splenocytes were transferred into recipients, or 10 million of each population was co-transferred.
Blood glucose levels were monitored for 13 weeks following transfer when all recipient mice were diabetic.
Bone marrow chimeras
Idd9 congenic and NOD mice 6 weeks of age were lethally
irradiated (950–1,000 Rad) and injected with bone marrow cells prepared from 5 week old NOD donors. Bone
marrow was isolated from the leg bones of donor mice
and resuspended at 50 million cells/ml. Following irradiation, recipients were injected iv with 10 million bone
marrow cells in PBS, and maintained on antibiotics in the
drinking water.
Islet transplantation
Islets were hand picked from 5–7 week old Idd9 congenic
and NOD donors. Typically 150–250 islets were isolated
from each pancreas, and 9–12 donors of each strain were
used for each experiment. Islets were isolated following
pancreas inflation with collagenase through the common
bile duct, as previously described [50]. Islets were then
cultured in hydrophobic 35 mm Petri dishes for 7 days in
10 % CO2 at 37°, and the media changed every 3 days.
RPMI 1640 containing 10 % FCS and supplemented with
glutamine and antibiotics was used throughout the procedure. Approximately 250 islets were transplanted under
the left kidney capsule of 11 week old NODScid recipients, as previously described [50]. The grafts were allowed
to revascularize for seven days before transfer of splenocytes from 8.3NODScid mice. 5–7 days after splenocyte
transfer the grafts were removed and fixed in 10 % NBF for
paraffin embedding. Sections (4 Pm) were cut and H&E
stained for analysis of graft integrity and infiltration.
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To score the extent of graft destruction adjacent sections
were stained with anti-insulin and anti-glucagon (Dako,
Carpinteria, 1/400) and scored as either healthy (normal
distribution of predominantly insulin-positive cells with
scattered glucagon-positive cells around the islet periphery) or collapsed/destroyed (few or no insulin-positive
cells, and the predominance of glucagon-positive cells giving the islet a 'collapsed' appearance in glucagon-stained
sections).
Immunoblotting
Islets were isolated from 5 week old mice and allowed to
recover in culture medium for 4–6 days before being stimulated with 1,000 U/ml IFNJ and 1,000 U/ml TNF (BD
Pharmingen, San Diego, CA), with each cytokine individually, or with medium alone, for 2 days. Cells were lysed
with RIPA buffer (containing 20 mmol/liter Tris, pH 7.5,
1 mmol/liter EDTA, 140 mmol/liter NaCl, 1% NP-40, 1
mmol/liter orthovanadate, 1 mmol/liter PMSF, and 10
Pg/ml aprotinin) and 20–150 ug protein loaded per lane
on a 12 % gel for western blot. Mouse anti-RIP (BD Transduction Labs, San Diego, CA) and rabbit anti-TRAF2
(Leinco, St. Louis, Missouri) antibodies were used for
immunodetection (Cell Signaling Technology). All membranes were stripped and reblotted with a mouse mAb to
actin to confirm equal protein loading (ICN Biomedicals). Densitometry was performed using ImageJ software
(Nih).
Islet cell death
To induce islet cell death, isolated islets from 5 week old
donors were cultured with 1,000 U/ml INFJ and 1,000–
5,000 U/ml TNF for 6 days. 50–100 islets were used per
assay. Islets were then incubated with the Molecular
Probes (Eugene, OR) Live/dead stain in RPMI-1640 for 45
minutes at 37'. Intact, unfixed islets were then transferred
to microscope slides, excess buffer removed using a
stretched Pasteur pipette, and a cover slip sealed over the
islets. Confocal images using 40× oil immersion lens of Zstack sections 50–100 Pm through each islet were taken.
The number of live and dead cells in each field was determined using ImageJ software.
Islet cell flow cytometry
Hand-picked islets from 5 week old donor Idd9 congenic
and NOD mice, or 4–6 month old B6 and B6.TNFR2KO
mice, were cultured in complete RPMI-1640 media for 4–
6 days to allow recovery and depletion of tissue-resident
leukocytes. Islets were then treated with medium, IFNJ,
TNF, or IFNJ +TNF for 48 hours. Cytokines were used at
1,000 U/ml unless otherwise stated. For blocking experiments islets were cultured with blocking anti-TNFR2 antibody (Pharmingen), or hamster IgG isotype control, for
1–2 hours prior to addition of cytokines. Islets were dispersed using 0.25% trypsin/EDTA for 4 min, washed and
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allowed to recover at 37' for 1 hour. Staining was carried
out for 30 min at 4'C using PE-labeld anti-TNFR2 (clone
HM102, Caltag), or with biotinylated anti-Fas (Jo2,
Pharmingen) and SA-APC, or the relevant isotype control.
7AAD was added for 10 min at RT to exclude dead cells,
and the samples analyzed immediately.
Statistical tests
In all cases where a p value is shown, a two-tailed,
unpaired Students' t-test was used to gauge significance,
except for comparisons of diabetes incidences in which
case the Kaplan-Meier survival test was used.
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Reviewers' comments
Reviewers report 1
Dr Matthiasvon Herrath
La Jolla Institute for Allergy and immunology, San
Diego, CA, United States

In this study, the author shows that genetic variation at
the Idd9 diabetes susceptibility locus determines the
resistance of pancreatic beta-cells to destruction. Susceptible NOD beta-cells show increased response to proinflammatory cytokines, enhanced cell death and
increased Fas upregulation, which is mediated by TNFR2.
TNFR2 lies within the Idd9 interval, and the diabetesassociated variant contains a mutation close to the TRAF2
binding site. In NOD beta-cells colocalization of TNFR2
with the adaptor TRAF2 is prolonged, thereby enhancing
susceptibility of NOD beta-cells to destruction. The
authors conclude that diabetes susceptibility is not only
determined by the immune system but also by the susceptibility of the target tissue to destruction and suggests that
protective islet TNFR2/TRAF2 signaling may result in
resistance to islet destruction and diabetes.
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General comments
This manuscript is interesting and very well written, the
figures are clear (especially Figures 1C and 7D are very
nice) and the conclusions correct. However, few specific
points have to be addressed, which are listed below.
Specific points to be addressed
• Figure 1: The islet infiltrate studies have been performed
with 12–14 week old NOD and Idd9 congenic mice, however, percentages of CD4 and CD8 T cells in peripheral
blood and secondary lymphoid organs were derived from
6-week old mice. For better comparison, it would have
been important to test secondary lymphoid organs and
peripheral blood from 12–14 week old mice. Please add
comment on whether the percentages of CD4 and CD8 T
cells remained the same in these organs at 12–14 weeks of
age.
Author's reply
We used young mice in these experiments to test whether
there were differences in the % CD8 T cells in the steady
state, before the onset of extensive insulitis, to try to distinguish against changes secondary to differences in insulitis. It is an important question though since the decrease
in % CD8 T cells may occur systemically during the progression of autoimmunity rather than being specific to the
islet environment. However, we have not found any evidence of this. We examined peripheral blood at 12 weeks
of age to compare the % CD8 T cells in the circulation to
that in the islet infiltrate, and observed a similar % CD8 T
cells in the peripheral blood of NOD and Idd9 mice
(NOD = 12.3 +/- 0.6, Idd9 = 13.6 +/- 0.9, n = 4 for each
strain), and a similar % CD4 T cells (NOD = 46.4 +/- 1.1,
Idd9 = 47.0 +/- 1.2, n = 4). There was also no difference in
the % CD8 T cells in spleen at 9 or 20 weeks of age,
although there was a slight increase in the % CD4 T cells
in Idd9 mice. We have therefore added to the results section a sentence that no difference in the % CD8 T cell was
observed systemically in older mice.

• Figure 2: It would have been better to perform the experiments described in Figure 2 with older recipients when
insulitis is already strongly ongoing.
Author's reply
We again wanted to try to test for primary differences
occurring in lymphoid organs before the effect of differences in insulitis influences events in these organs. It was
also important to use younger mice because there is evidence that the pancreatic lymph nodes are not involved in
diabetogenesis after 10 weeks of age since diabetes proceeds at the same rate if the panLN are removed at this
time (Gagnerault et al, J Exp Med. 2002 Aug
5;196(3):369-77). In this respect, it is therefore appropriate to examine the effect of the Idd9 panLN environment

http://www.biology-direct.com/content/2/1/5

on the priming of islet-specific CD8 T cell responses in
recipients of an age where priming in the panLN is relevant.
• Figure 3A: The author states that there is no evidence
that Idd9 congenic splenocytes are able to regulate diabetes induction (bottom of page 6). Which is the kinetic of
diabetes incidence in NODScid recipients when only 10
million NOD splenocytes are transferred? If the recipients
develop faster diabetes than in the presence of 10 million
NOD splenocytes together with 10 million Idd9 splenocytes, then Idd9 splenocytes have a regulatory potential.
Author's reply
Transferring 10 million NOD splenocytes induces diabetes with slower kinetics than 10 million NOD + 10 million Idd9 splenocytes (67 % diabetes by 13 weeks post
transfer compared to 100 % diabetes, respectively). 10
million Idd9 splenocytes induce diabetes in 50 % recipients at this timepoint (n = 6 each group). This further supports the conclusion that there is no evidence that Idd9
splenocytes have regulatory activity, and we have added a
sentence to the results section describing this data.

• Figure 5A: The author explains in the text that TNFR2
mRNA expression has been shown to be induced in islet
cells during diabetes progression (Ref. 18), so why do the
authors then show TNFR2 flow cytometry stain in 5-weekold young mice instead of choosing older pre-diabetic
mice as shown in Figure 5B with pancreas histology?
Author's reply
We used islets from young donors to test TNFR2 expression by flow cytometry partly in order to reduce the likelihood of contamination with TNFR2+ lymphocytes, but
primarily since it is difficult to isolate islets when there is
extensive insulitis present. This is true both in terms of isolating sufficient numbers of islets and also because they
do not survive well in culture, presumably because of the
large number of infiltrating cells. We treated the islets
from young donors with cytokines in vitro to try to mimic
the inflammation that would occur in vivo, but did not
consistently detect an increase in the expression of TNFR2
following cytokine treatment.

• Figure 6: Please correct in the figure legend for Figure 6A
that experiments were performed with B6 and not with
Idd9 and NOD mice. Please use for Figures 6D and 6E and
for the figure legend the same figure description (for
example I+T+R2, I+T). Please explain why in Figure 6D
and 6E IFN- treatment was taken as negative control and
not medium only treatment as shown in Figures A-C.
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Author's reply
We have corrected the labeling in the legend for Figure 6A,
and also made the labeling in Figures 6D and 6E consistent. With regard to the use of medium or IFN alone as a
control in these experiments, there is no difference in Fas
expression between Idd9 and NOD in either medium
treated or IFN-treated islets and IFN was used as a control
in the later experiments only to reduce the number of variables that differ between control and experiment.
Reviewers report 2
Harald Von Boehmer
Harvard Medical School, Dana-Farber Cancer Institute,
Boston, MA, United States

• The manuscript by Hill et al. addresses the question
whether resistance of target tissue (insulin-producing E
cells) to autoimmune destruction contributes to diabetes
susceptibility by analyzing islets in Idd9 congenic and
NOD strains of mice. The authors show less abundance of
CD8 T cells in Idd9 congenic islets, less induction of Fas
by TNFRII signaling and note a difference in sequence in
the TNFRII receptor in Idd9 congenic versus NOD mice
adjacent to the TRAF2 binding site. They argue that this
difference may be responsible for stronger TNFRII-TRAF2
association in NOD mice, resulting in stronger cytokine
signaling which may be responsible (how?) for the
increased percentage of CD8 T cells in NOD islet infiltrates. The authors leave open whether increased Fas
expression in NOD islets directly contributes to increased
cytotoxicity by CD8 T cells and it is still a matter of debate
how much direct cytotoxicity by CD8 T cells contributes
to the final stages of E cell destruction in the NOD model
of type 1 diabetes.
Author's reply
We do not yet know how increased cytokine signaling in
NOD islets may increase the % CD8 T cells. However,
cytokine signalling in islets is known to increase expression of chemokines and cytokines that promote T cell
recruitment and survival. It is also interesting to consider
the possibility that since CD8 T cells seem to be specifically affected, it is perhaps direct interaction between target and CD8 T cells that results in increased T cell survival
in NOD islets. We hope to address this question in future
work.
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which critical islet responses occur, and the downstream
pathways that are key to diabetes protection, will be
important questions to answer.
• The authors attempt to rule out that the relative resistance of Idd9 congenic mice has to do with genes expressed
in hemopoietic cells but these studies are somewhat limited: hemopoietic cells from Idd9 congenic mice cause
diabetes with a delayed onset in NOD mice and in experiments aimed at depleting host cells in Idd9 congenic
mice injected with NOD hemopoietic cells 30% host cells
were still present. This leaves open the question whether
the Idd9 associated resistance becomes manifest in both E
cells as well as hemopoietic cells. It is clear, however, that
the TNFRII receptor gene is located in the Idd9 interval
and hence represents at least one good candidate gene
contributing to Idd9-mediated resistance. How the Idd9
TNFRII gene contributes to resistance is still largely an
open question and may involve reduced chemokine,
cytokine and/or Fas levels.
Author's reply
The Idd9 congenic interval in the strain used in these studies contains at least 3 distinct genes that influence diabetes
susceptibility, and we agree that it is very possible that
both islet and hematopoetic cells are affected by either the
same or different genetic variants in the Idd9 interval.

• Minor point: Ref. 41 refers to a CD4 not CD8 T cellmediated model of diabetes.
Author's reply
We have removed reference 41 from the discussion.
Reviewers report 3
Ciriaco Piccirillo
Dept. Microbiology and Immunology, McGill University, Montreal, Canada (nominated by Ethan Shevach,
National Institute of Allergy and Infectious Diseases,
National Institutes of Health Cellular Immunology Section, Laboratory of Immunology, Bethesda, MD United
States).

This reviewer provided no comments for publication, due
to personal circumstances.

We used Fas induction primarily as a marker of cytokine
responsiveness. There is little evidence that Fas-deficiency
alone protects islets against autoimmune destruction, but
increased Fas expression is only one of a wide program of
changes is induced in islets by cytokine exposure. The
work we present here provides evidence that genetic variation in islet responses to cytokines contributes to the progression of insulitis to overt autoimmunity. The stage at
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Additional material
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Additional File 1
Chimerism data for the experiment in Figure 3D. This figure shows the
%Thy1.1+ cells within CD4 and CD8 T cell populations for secondary
lymphoid organs in irradiated Idd9 (circles) and NOD (filled diamonds)
recipients. No difference in %Thy1.1 (donor) cells between Idd9 congenic and NOD recipients is observed.
Click here for file
[http://www.biomedcentral.com/content/supplementary/17456150-2-5-S1.pdf]
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